Abstract
Opicapone (OPC), a once-daily catechol-O-methyltransferase inhibitor, proved to be effective in treating end-of-dose motor fluctuations in Parkinson's disease (PD) patients in two large multinational trials. We evaluated the efficacy of OPC in PD patients with motor fluctuations according to different levodopa daily intakes.Image 1
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
